alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 140 (Thursday, July 23, 2009)]
[Notices]
[Page 36497]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-17432]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel, ARRA-RC2-SEP 8.
    Date: July 31, 2009.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20814 (Telephone 
Conference Call).
    Contact Person: Rebecca J. Ferrell, PhD, Scientific Review 
Officer, National Institute on Aging, Gateway Building 2C212, 7201 
Wisconsin Avenue, Bethesda, MD 20814, 301-402-7703, 
<a href="/cdn-cgi/l/email-protection#90f6f5e2e2f5fcfce2fad0fdf1f9fcbefef9f8bef7ffe6"><span class="__cf_email__" data-cfemail="ddbbb8afafb8b1b1afb79db0bcb4b1f3b3b4b5f3bab2ab">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel, ARRA-RC2-SEP-15.
    Date: August 19, 2009.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20814. (Telephone 
Conference Call)
    Contact Person: Ramesh Vemuri, PhD, Chief, Scientific Review 
Branch, National Institute on Aging, National Institutes of Health, 
7201 Wisconsin Avenue, Suite 2C-212, Bethesda, MD 20892, 301-402-
7700, <a href="/cdn-cgi/l/email-protection#9eece8acadecdef0f7f6b0f9f1e8"><span class="__cf_email__" data-cfemail="4a383c7879380a242322642d253c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research; 93.701, ARRA Related Biomedical Research and Research 
Support Awards, National Institutes of Health, HHS)

    Dated: July 16, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-17432 Filed 7-22-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
# 2022-32 Industry Directory

# Definitions

https://data.bls.gov/cgi-bin/forms/emp
Exhibit 13.2


                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
           AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     I, Dafna Gruber, as Chief Financial Officer of Alvarion Ltd. (the
"Company"), certify, pursuant to 18 U.S.C.ss. 1350, as adopted by Section 906 of
the Sarbanes-Oxley Act of 2002, that to my knowledge:

     (1)  the accompanying Amendment No. 1 to the Annual Report on Form 20-F for
          the fiscal year ended December 31, 2004 as filed with the U.S.
          Securities and Exchange Commission (the "Report") fully complies with
          the requirements of Section 13(a) or 15(d) of the Securities Exchange
          Act of 1934, as amended; and

     (2)  the information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.

Dated: February 9, 2006

                                        /s/ Dafna Gruber
                                        -------------------------
                                        Dafna Gruber
                                        Chief Financial Officer

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 13 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                       January 8, 2003.
Whereas on December 14, 2002, the Grand Valley State University Lakers won the 
        2002 NCAA Division II Football National Championship by defeating 
        Valdosta State University;
Whereas this national championship is the school's first in a varsity sport;
Whereas the Lakers won the 2002 Great Lakes Intercollegiate Athletic Conference 
        (GLIAC) Football Championship with a perfect 9-0 record in league play;
Whereas the Lakers completed the 2002 season with a perfect 14-0 record, and won 
        33 of its last 34 games;
Whereas Head Coach Brian Kelly has been with the team since 1991, and has led 
        the team to a 104-34-2 overall record;
Whereas the Lakers returned 51 letter winners, including 16 starters from the 
        2001 team that fell only to North Dakota in the NCAA Division II 
        National Championship game;
Whereas the Lakers placed 18 players on the 2002 All-GLIAC team;
Whereas quarterback Curt Anes was named the GLIAC Player of the Year for the 
        second straight year and earned the 2002 Harlon Hill Trophy as NCAA 
        Division II's most outstanding player;
Whereas the Lakers' defense dominated opponents by ranking 34th in the Nation in 
        rushing defense and recording 58 quarterback sacks;
Whereas the students, alumni, faculty, and fans of Grand Valley State University 
        showed their support by helping the Lakers set a GLIAC record for 
        regular-season attendance; and
Whereas the Lakers have displayed great strength, ability, and perseverance this 
        season and have made the State of Michigan proud: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) congratulates the Grand Valley State University Lakers for 
        winning the 2002 NCAA Division II Football National Championship and 
        recognizes all the players, coaches, and support staff who were 
        instrumental in this achievement;
            (2) requests that the President recognize the accomplishments of the 
        2002 Grand Valley State University football team and invite them to 
        Washington, D.C., for a White House ceremony for national championship 
        teams; and
            (3) directs the Clerk of the House of Representatives to transmit an 
        enrolled copy of this resolution to Grand Valley State University for 
        appropriate display.
            Attest:

                                                                          Clerk.
```
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 135 Introduced in House (IH)]

108th CONGRESS
  1st Session
H. RES. 135

     Providing amounts for the expenses of the Committee on House 
           Administration in the One Hundred Eighth Congress.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 11, 2003

   Mr. Ney (for himself and Mr. Larson of Connecticut) submitted the 
  following resolution; which was referred to the Committee on House 
                             Administration

_______________________________________________________________________

                               RESOLUTION

 
     Providing amounts for the expenses of the Committee on House 
           Administration in the One Hundred Eighth Congress.

    Resolved, 

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES.

    For the expenses of the Committee on House Administration 
(hereafter in this resolution referred to as the ``Committee''), 
including the expenses of all staff salaries, there shall be paid, out 
of the applicable accounts of the House of Representatives for 
committee salaries and expenses, not more than $10,374,974 for the One 
Hundred Eighth Congress.

SEC. 2. SESSION LIMITATIONS.

     Of the amount specified in section 1--
            (1) not more than $5,028,573 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2003, and ending immediately before noon on January 
        3, 2004; and
             (2) not more than $5,346,401 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2004, and ending immediately before noon on January 
        3, 2005.

SEC. 3. VOUCHERS.

     Payments under this resolution shall be made on vouchers 
authorized by the Committee, signed by the Chairman of the Committee, 
and approved in the manner directed by the Committee on House 
Administration.

SEC. 4. REGULATIONS.

     Amounts made available under this resolution shall be expended in 
accordance with regulations prescribed by the Committee on House 
Administration.
                                 <all>
```
[Federal Register Volume 74, Number 141 (Friday, July 24, 2009)]
[Notices]
[Pages 36728-36729]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-17590]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Stem Cell and Animal Model.
    Date: August 5, 2009.
    Time: 10 a.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Joanne T. Fujii, PhD, Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 4184, MSC 7850, Bethesda, MD 20892, (301) 435-
1178, <a href="/cdn-cgi/l/email-protection#dfb9aab5b6b6b59fbcacadf1b1b6b7f1b8b0a9"><span class="__cf_email__" data-cfemail="335546595a5a59735040411d5d5a5b1d545c45">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing

[[Page 36729]]

limitations imposed by the review and funding cycle.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Vascular Biology and Hemostasis.
    Date: August 10-11, 2009.
    Time: 12 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Manjit Hanspal, PhD, Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 4138, MSC 7804, Bethesda, MD 20892, 301-435-
1195, <a href="/cdn-cgi/l/email-protection#f99198978a89989594b99a8a8bd7979091d79e968f"><span class="__cf_email__" data-cfemail="96fef7f8e5e6f7fafbd6f5e5e4b8f8fffeb8f1f9e0">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: July 17, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-17590 Filed 7-23-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 10.34

 

On January 30, 2013, the Compensation Committee of Supernus Pharmaceuticals, Inc. (the “Company”) approved modifications of the compensation of its executive officers, as follows:

 

The annual base salary of Jack A. Khattar, the Company’s President and Chief Executive Officer, was increased from $450,000 to $463,500.  Mr. Khattar was awarded a 2012 bonus of $247,766 and was granted options to purchase 300,000 shares of common stock and a stock appreciation rights award for 92,000 shares of common stock.

 

The annual base salary of Gregory S. Patrick, the Company’s Vice President and Chief Financial Officer, was increased from $300,000 to $309,000.  Mr. Patrick was awarded a 2012 bonus of $102,450 and was granted options to purchase 70,000 shares of common stock.

 

The annual base salary of Stefan K.F. Schwabe, MD, Ph.D., the Company’s Executive Vice President and Chief Medical Officer, was increased from $330,000 to $332,875.  Dr. Schwabe was awarded a 2012 bonus of $58,261 and was granted options to purchase 20,000 shares of common stock.

 

The annual base salary of Padmanabh P. Bhatt, Ph.D., the Company’s Senior Vice President, Intellectual Property and Chief Scientific Officer, was increased from $306,000 to $315,180.  Dr. Bhatt was awarded a 2012 bonus of $96,412 and was granted options to purchase 80,000 shares of common stock.

 

The annual base salary of James W. Bryan, Ph.D., the Company’s Vice President of Business Development, was increased from $250,000 to $257,500.  Dr. Bryan was awarded a 2012 bonus of $73,156 and was granted options to purchase 70,000 shares of common stock.

 

Victor Vaughn, Senior Vice President, Sales was hired in January 2013.  His annual base salary is $275,000.  In addition, he is eligible to receive an annual target bonus of 30% of his annual base salary, prorated for 2013 based on his starting date. Mr. Vaughn was also granted options to purchase 85,000 shares of common stock .

 

These increases were the result of the Compensation Committee’s annual compensation review for executive officers.  These increases in annual base salary became effective on January 1, 2013.  Vesting for all stock option grants will occur annually in equal increments over a four year period and the exercise price for each grant is $7.90 per share, based on the closing price of February 5, 2013, the date of approval of the grants by the full board of directors.  All other terms and conditions of the Company’s compensatory arrangements with these executive officers remain unchanged.
##### 



Exhibit 31.2
 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER  PURSUANT TO RULE 13a  14(a) UNDER THE  SECURITIES EXCHANGE ACT OF 1934
  1.
    
    I have reviewed this quarterly report on Form 10-Q of Home Diagnostics, Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of
the registrant as of, and for, the periods presented in this report;4.
    
    The registrants other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)):
 (a)
    
    Designed such
disclosure controls
and procedures, or
caused such
disclosure controls
and procedures to
be designed under
our supervision, to
ensure that
material
information
relating to the
registrant,
including its
consolidated
subsidiaries, is
made known to us by
others within those
entities,
particularly during
the period in which
this report is
being prepared;(b)
    
    Evaluated the
effectiveness of
the registrants
disclosure controls
and procedures and
presented in this
report our
conclusions about
the effectiveness
of the disclosure
controls and
procedures, as of
the end of the
period covered by
this report based
on such evaluation;
and(c)
    
    Disclosed in this
report any change
in the registrants
internal control
over financial
reporting that
occurred during the
registrants most
recent fiscal
quarter (the
registrants fourth
fiscal quarter in
the case of an
annual report) that
has materially
affected, or is
reasonably likely
to materially
affect, the
registrants
internal control
over financial
reporting; and
 5.
    
    The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrants auditors and the audit committee of the registrants board of
directors (or persons performing the equivalent functions):
 (a)
    
    All significant deficiencies and material
weaknesses in the design or operation of
internal control over financial reporting
which are reasonably likely to adversely
affect the registrants ability to
record, process, summarize and report
financial information; and(b)
    
    Any fraud, whether or not material, that
involves management or other employees
who have a significant role in the
registrants internal control over
financial reporting.
  By:
    
    /s/ Ronald L. RubinRonald L. Rubin
Vice President and Chief Financial Officer
(principal financial and accounting officer)
 25
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               MAR-31-1997
<CASH>                                           8,277
<INT-BEARING-DEPOSITS>                             336
<FED-FUNDS-SOLD>                                   700
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     20,868
<INVESTMENTS-CARRYING>                          10,848
<INVESTMENTS-MARKET>                            10,828
<LOANS>                                        143,081
<ALLOWANCE>                                      1,183
<TOTAL-ASSETS>                                 194,155
<DEPOSITS>                                     171,836
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                                962
<LONG-TERM>                                        752
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           345
<OTHER-SE>                                      20,260
<TOTAL-LIABILITIES-AND-EQUITY>                 194,155
<INTEREST-LOAN>                                  3,189
<INTEREST-INVEST>                                  479
<INTEREST-OTHER>                                    24
<INTEREST-TOTAL>                                 3,692
<INTEREST-DEPOSIT>                               1,555
<INTEREST-EXPENSE>                               1,596
<INTEREST-INCOME-NET>                            2,096
<LOAN-LOSSES>                                       50
<SECURITIES-GAINS>                                (28)
<EXPENSE-OTHER>                                  1,301
<INCOME-PRETAX>                                    940
<INCOME-PRE-EXTRAORDINARY>                         940
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       714
<EPS-PRIMARY>                                     0.52
<EPS-DILUTED>                                     0.52
<YIELD-ACTUAL>                                       0
<LOANS-NON>                                      1,091
<LOANS-PAST>                                       112
<LOANS-TROUBLED>                                    96
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 1,177
<CHARGE-OFFS>                                       51
<RECOVERIES>                                         7
<ALLOWANCE-CLOSE>                                1,183
<ALLOWANCE-DOMESTIC>                               713
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                            470
        

</TABLE>
**EXHIBIT
        32.1**
 
 **CERTIFICATION
        BY THE CHIEF EXECUTIVE OFFICER**
 **PURSUANT
        TO 18 U.S.C. SECTION 1350,**
 **AS
        ADOPTED PURSUANT TO**
 **SECTION
        906 OF THE SARBANES-OXLEY ACT OF 2002**
 
 In
        connection with the Annual Report on Form 10-KSB/A of Syndication, Inc. (the
        "Company") for the period ended December 31, 2007 as filed with the Securities
        and Exchange Commission on the date hereof (the "Report"), the undersigned,
        Brian Sorrentino, President and Chief Executive Officer of the Company, hereby
        certifies, pursuant to 18 U.S.C. Section 1350, that:
 
 (1)
        The
        Report fully complies with the requirements of Section 13(a) or 15(d) of
        the
        Securities Exchange Act of 1934; and
 
 (2)
        The
        information contained in the Report fairly presents, in all material respects,
        the financial condition and results of operations of the Company.
  *Dated:*May 2, 2008
              *By:*
              */s/
                  Brian Sorrentino**Brian
                  Sorrentino**Acting Chief
                  Executive Officer*